Arbutus Biopharma Võlakoormus 2024

Mis teeb Arbutus Biopharma?

Arbutus Biopharma Corp is a biopharmaceutical company that focuses on developing novel treatment methods for viral diseases. The company, based in Vancouver, Canada, was founded in 2008. The history of Arbutus Biopharma Corp began with the merger of Tekmira Pharmaceuticals and OnCore Biopharma in 2015. The merger strengthened the company and expanded its ability to develop innovative therapies for Hepatitis B and Hepatitis D viruses. The ability to bring the companies together also demonstrates the team, consisting of experienced experts from various areas such as the healthcare industry, biotech engineering, finance, and pharmacy. The business model of Arbutus Biopharma Corp is to explore, develop, and market novel treatment methods for viral diseases. Marketing is done through partnerships with other companies that commercialize the products. The company relies on research and development agreements to enter into synergistic partnerships that work on the same wavelength. One of the key divisions of Arbutus Biopharma Corp is the development of RNA interference (RNAi) therapies. These therapies aim to suppress the genetic information that leads to viral replication in cells. The company has an extensive patent portfolio and comprehensive expertise in the field of RNAi therapy. RNAi therapy opens up a new paradigm in the treatment of viral diseases. The company has also developed products such as the HBV Antisense platform. The HBV Antisense platform utilizes a special type of RNA-based medication to suppress the production of proteins necessary for the replication of the Hepatitis B virus. This strategy allows for the reduction of viral RNA replication and strengthens the immune system to fight against or prevent viral infections. The company also pursues an advanced pipeline in the preclinical phase to develop a melanocortin receptor antagonist and an artificial antibody against Hepatitis B. Another business area of Arbutus Biopharma Corp is collaboration with other companies to outsource innovative technologies and products. One of the key partnerships is with Roivant Sciences Ltd. Roivant Sciences Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative therapy approaches. The partnership between Arbutus Biopharma Corp and Roivant Sciences Ltd creates a win-win situation for both, bringing about synergies and enabling capital and risk sharing. In summary, Arbutus Biopharma Corp is a biopharmaceutical company that focuses on the development of novel therapies for viral diseases. The company has a broad portfolio of innovative products in the field of RNAi therapy and HBV Antisense platform. Arbutus Biopharma Corp strives to achieve advancements in the development of therapies for viral diseases through partnerships and alliances with other companies. Arbutus Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.